Navigation Links
ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/6/2008

pproval or actions); uncertainties and risks regarding market acceptance of and demand for ISTA's approved products and the impact of competitive products and pricing; uncertainties and risks related to ISTA's ability to properly manage its growth; uncertainties and risks regarding the continued timely performance by ISTA's strategic partners of their respective obligations under existing collaborations and licensing arrangements; uncertainties and risks related to the continued availability of third party sourced products and raw materials on commercially reasonable terms, or at all; uncertainties and risks related to successful compliance with FDA and or other governmental regulations applicable to ISTA's facilities, products and/or business; uncertainties and risks related to the scope, validity, and enforceability of patents related to ISTA's products and technologies and the impact of patents and other intellectual property rights held by third parties; and such other risks and uncertainties as detailed from time to time in ISTA's public filings with the U.S. Securities and Exchange Commission, including but not limited to ISTA's Annual Report on Form 10-K for the year ended December 31, 2006, and its Forms 10-Q for the quarters ended March 31, 2007, June 30, 2007, and September 30, 2007.

ISTA Pharmaceuticals, Inc.

Consolidated Statements of Operations

(in thousands, except per share data)

(unaudited)

Three Months Ended Year Ended

December 31, December 31,

2007 2006 2007 2006 Revenue:

Product sales, net $ 19,092 $ 12,190 $ 58,589 $ 32,729

License revenue 70 70 278 278 Total revenue 19,162 12,260 58,86
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ADVENTRX Pharmaceuticals to Report Fourth Quarter and Year End 2007 Results
2. Acura Pharmaceuticals, Inc. Reports 2007 4th Quarter and Annual Financial Results; Sets 2008 Expectations
3. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
4. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
5. MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
6. SGX Pharmaceuticals Schedules Teleconference and Webcast for Fourth Quarter and Full Year 2007 Results
7. NPS Pharmaceuticals to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
8. NuRx Pharmaceuticals Retains Russo Partners for Investor Relations, Corporate Communications Counsel
9. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
10. Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds
11. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... BOSTON , May 4, 2015 ... development of novel therapies for neurological and neuropsychiatric ... has initiated dosing of Alzheimer,s patients in a ... candidate, GC021109, a compound developed as a potential ... disease is innovative in that it both promotes ...
(Date:5/4/2015)... 4, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ... independent team of researchers from South ... (TB4) plays an important role in accelerating the ... an experimental mouse model, by promoting blood vessel ... dermal tissue.  The research found that the underlying ...
(Date:5/4/2015)... - New Massive Open Online Course (MOOC) ... United States Medical Licensing Examination Elsevier ... information products and services, announced today that it has ... to help medical students prepare for the United States ... most daunting of the three exams medical students must ...
(Date:5/1/2015)... 2015  Northwest Biotherapeutics (NASDAQ: NWBO ) ("NW ... therapies for solid tumor cancers, announced today that the ... of a $40 million investment from Woodford investment funds ... $25 million in NW Bio on November 19, 2014.  ... with the Company for a further $40 million investment ...
Breaking Biology Technology:GliaCure Initiates Phase 1b Dosing in Alzheimer's Patients 2Researchers Report that Thymosin B4 has a Major Role in Dermal Burn Wound Healing 2Researchers Report that Thymosin B4 has a Major Role in Dermal Burn Wound Healing 3Elsevier's Free MOOC Prepares Med Students for Licensing Exam 2Elsevier's Free MOOC Prepares Med Students for Licensing Exam 3NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing 2NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing 3
... , Sylviane Komesli, Martine Page, and ... Laboratoires Fournier S.A., France , ... and type II receptors form ligand dependent heteromeric signaling complexes, in which ... primary receptor. In the present study, we investigated the feasibility of using ...
... , ... radiometric screening assays. The Wallac MicroBeta effectively measures both plate types. , ... one above the sample and one below. , ... are conducted with the upper PM tube only. A comparison is made ...
... Heidi Grecsek , ... 710 Bridgeport Avenue , ... , The Clean Air Act amendments of 1990 ... content. Oxygenated fuel is desirable because it burns more completely, thereby reducing tailpipe emissions. ...
Cached Biology Technology:Use of FlashPlate Technology for In Vitro Measurement of 125I-Labeled TGF-1 Binding on Chimeric Extracellular Domain of Type II Transforming Growth Factor Receptor 2Use of FlashPlate Technology for In Vitro Measurement of 125I-Labeled TGF-1 Binding on Chimeric Extracellular Domain of Type II Transforming Growth Factor Receptor 3Use of FlashPlate Technology for In Vitro Measurement of 125I-Labeled TGF-1 Binding on Chimeric Extracellular Domain of Type II Transforming Growth Factor Receptor 4Use of FlashPlate Technology for In Vitro Measurement of 125I-Labeled TGF-1 Binding on Chimeric Extracellular Domain of Type II Transforming Growth Factor Receptor 5Use of FlashPlate Technology for In Vitro Measurement of 125I-Labeled TGF-1 Binding on Chimeric Extracellular Domain of Type II Transforming Growth Factor Receptor 6Use of FlashPlate Technology for In Vitro Measurement of 125I-Labeled TGF-1 Binding on Chimeric Extracellular Domain of Type II Transforming Growth Factor Receptor 7Counting FlashPlates on the Wallac MicroBeta 2Counting FlashPlates on the Wallac MicroBeta 3Analysis of Fuel Oxygenates by U.S. EPA Method 8260B Using Headspace Trap with GC/MS 2Analysis of Fuel Oxygenates by U.S. EPA Method 8260B Using Headspace Trap with GC/MS 3Analysis of Fuel Oxygenates by U.S. EPA Method 8260B Using Headspace Trap with GC/MS 4
(Date:4/17/2015)... 17, 2015 Increasing ... technological advancement to drive biometric systems market in ...   According to a recently released ... &  Opportunities, 2020 ", biometric systems market in ... growth at CAGR of over 22% through 2020. ...
(Date:4/10/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ) ... Profiles - NEC" report to their offering. ... continue to supply a range of IT security management ... focus on the development of a Big Data and ... the Asia-Pacific region is a ...
(Date:4/2/2015)... -- At its 2015 ACMG Annual Clinical Genetics Meeting ... American College of Medical Genetics and Genomics (ACMG) announced ... Members of the ACMG Board of Directors serve as ... its policies and programs. ACMG is the national organization ... eventful time in medical genetics and genomics.  We are ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NEC Security Competitive Profile 2015 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8
... Ind. - A new, high-resolution, interactive map of U.S. ... the emissions aren,t all where we thought. "For ... northeastern United States, and it,s looking like the southeastern ... estimated previously," says Kevin Gurney, an assistant professor of ...
... Yale Universitys Scott A. Strobel, Professor of Molecular ... Schering-Plough Research Institute Award. The award is ... Biology to recognize outstanding scientific contributions made by ... will give the award lecture, titled Three Views ...
... chemical communicator, carrying impulses from neurons to skeletal ... system. Now researchers at the University of Illinois ... component of the relay system that allows acetylcholine ... appear in the current issue of Nature Structure ...
Cached Biology News:'Revolutionary' CO2 maps zoom in on greenhouse gas sources 2'Revolutionary' CO2 maps zoom in on greenhouse gas sources 3'Revolutionary' CO2 maps zoom in on greenhouse gas sources 4'Revolutionary' CO2 maps zoom in on greenhouse gas sources 5Yale University's Strobel recognized for work on RNA 2Researchers 'see' structure of open nicotinic acetylcholine ion channels 2Researchers 'see' structure of open nicotinic acetylcholine ion channels 3
...
...
Experion HighSens chips are the microfluidic chips used to perform high-sensitivity RNA analysis (picogram levels) with the Experion automated electrophoresis system. Each chip has the capacity to ru...
... Activator of Caspase/DIABLO Liquid. In 100 ... FREEZE/THAW CYCLES. Amino acid residues 56 - 239 ... ® sequence was expressed in and purified ... along with cytochrome c during apoptosis ...
Biology Products: